Adel Alhazzani, Fahad S Alajlan, Ali M Alkhathaami, Fahmi Mohammed Al-Senani, Taim A Muayqil, Saeed A Alghamdi, Ammar AlKawi, Saeed AlZahrani, Majid Bakheet, Mohammed Aljohani, Nouran Taher, Abdulkarim Almutairi, Mustafa AlQarni, Sadiq Alsalman, Saeed A Alqahtani, Nouf Almansour, Laila Abukhamsin, Amr Mouminah, Nehal Almodarra, Gamal Mohamed, Meshal Almodhy, Eid Albogumi, Mohamad Alzawahmah, Abdulrahman Alreshaid, Naveed Akhtar, Muhammad Shazam Hussain, Gregory W Albers, Ashfaq Shuaib
{"title":"在急诊室开始治疗时，缩短治疗时间对脑卒中和高危 TIAs 的疗效（SHORTER-研究）。","authors":"Adel Alhazzani, Fahad S Alajlan, Ali M Alkhathaami, Fahmi Mohammed Al-Senani, Taim A Muayqil, Saeed A Alghamdi, Ammar AlKawi, Saeed AlZahrani, Majid Bakheet, Mohammed Aljohani, Nouran Taher, Abdulkarim Almutairi, Mustafa AlQarni, Sadiq Alsalman, Saeed A Alqahtani, Nouf Almansour, Laila Abukhamsin, Amr Mouminah, Nehal Almodarra, Gamal Mohamed, Meshal Almodhy, Eid Albogumi, Mohamad Alzawahmah, Abdulrahman Alreshaid, Naveed Akhtar, Muhammad Shazam Hussain, Gregory W Albers, Ashfaq Shuaib","doi":"10.1177/17474930241237120","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Following transient ischemic attack (TIA) and minor stroke, the risk of recurrent stroke can be significantly reduced with short-duration dual antiplatelet therapy (DAPT). We wish to investigate whether 10 days of DAPT is as effective as 21 days' treatment.</p><p><strong>Study design: </strong>This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA + clopidogrel) is non-inferior to 21 days of DAPT in patients with acute ischemic stroke (AIS) or high-risk TIA. In both groups, DAPT is started within 24 hours of symptom onset. This study is being conducted in approximately 15 study sites in the Kingdom of Saudi Arabia. The planned sample size is 1932.</p><p><strong>Outcomes: </strong>Non-inferiority of 10 days compared to 21 days of DAPT in the prevention of the composite endpoint of stroke and death at 90 days in AIS/TIA patients. The primary safety outcome is major intra-cranial and systemic hemorrhage.</p><p><strong>Study period: </strong>Enrolment started in the second quarter of 2023, and the completion of the study is expected in the fourth quarter of 2025.</p><p><strong>Discussion: </strong>The trial is expected to show that 10 days of DAPT is non-inferior for the prevention of early recurrence of vascular events in patients with high-risk TIAs and minor strokes.</p>","PeriodicalId":14442,"journal":{"name":"International Journal of Stroke","volume":" ","pages":"830-834"},"PeriodicalIF":6.3000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stroke and high-risk TIA outcomes with reduction of treatment duration when treatment initiated in emergency rooms (SHORTER-study).\",\"authors\":\"Adel Alhazzani, Fahad S Alajlan, Ali M Alkhathaami, Fahmi Mohammed Al-Senani, Taim A Muayqil, Saeed A Alghamdi, Ammar AlKawi, Saeed AlZahrani, Majid Bakheet, Mohammed Aljohani, Nouran Taher, Abdulkarim Almutairi, Mustafa AlQarni, Sadiq Alsalman, Saeed A Alqahtani, Nouf Almansour, Laila Abukhamsin, Amr Mouminah, Nehal Almodarra, Gamal Mohamed, Meshal Almodhy, Eid Albogumi, Mohamad Alzawahmah, Abdulrahman Alreshaid, Naveed Akhtar, Muhammad Shazam Hussain, Gregory W Albers, Ashfaq Shuaib\",\"doi\":\"10.1177/17474930241237120\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Following transient ischemic attack (TIA) and minor stroke, the risk of recurrent stroke can be significantly reduced with short-duration dual antiplatelet therapy (DAPT). We wish to investigate whether 10 days of DAPT is as effective as 21 days' treatment.</p><p><strong>Study design: </strong>This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA + clopidogrel) is non-inferior to 21 days of DAPT in patients with acute ischemic stroke (AIS) or high-risk TIA. In both groups, DAPT is started within 24 hours of symptom onset. This study is being conducted in approximately 15 study sites in the Kingdom of Saudi Arabia. The planned sample size is 1932.</p><p><strong>Outcomes: </strong>Non-inferiority of 10 days compared to 21 days of DAPT in the prevention of the composite endpoint of stroke and death at 90 days in AIS/TIA patients. The primary safety outcome is major intra-cranial and systemic hemorrhage.</p><p><strong>Study period: </strong>Enrolment started in the second quarter of 2023, and the completion of the study is expected in the fourth quarter of 2025.</p><p><strong>Discussion: </strong>The trial is expected to show that 10 days of DAPT is non-inferior for the prevention of early recurrence of vascular events in patients with high-risk TIAs and minor strokes.</p>\",\"PeriodicalId\":14442,\"journal\":{\"name\":\"International Journal of Stroke\",\"volume\":\" \",\"pages\":\"830-834\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Stroke\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17474930241237120\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Stroke","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17474930241237120","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Stroke and high-risk TIA outcomes with reduction of treatment duration when treatment initiated in emergency rooms (SHORTER-study).
Background: Following transient ischemic attack (TIA) and minor stroke, the risk of recurrent stroke can be significantly reduced with short-duration dual antiplatelet therapy (DAPT). We wish to investigate whether 10 days of DAPT is as effective as 21 days' treatment.
Study design: This is an open-label, randomized, parallel-group study comparing whether 10 days of DAPT treatment (ASA + clopidogrel) is non-inferior to 21 days of DAPT in patients with acute ischemic stroke (AIS) or high-risk TIA. In both groups, DAPT is started within 24 hours of symptom onset. This study is being conducted in approximately 15 study sites in the Kingdom of Saudi Arabia. The planned sample size is 1932.
Outcomes: Non-inferiority of 10 days compared to 21 days of DAPT in the prevention of the composite endpoint of stroke and death at 90 days in AIS/TIA patients. The primary safety outcome is major intra-cranial and systemic hemorrhage.
Study period: Enrolment started in the second quarter of 2023, and the completion of the study is expected in the fourth quarter of 2025.
Discussion: The trial is expected to show that 10 days of DAPT is non-inferior for the prevention of early recurrence of vascular events in patients with high-risk TIAs and minor strokes.
期刊介绍：
The International Journal of Stroke is a welcome addition to the international stroke journal landscape in that it concentrates on the clinical aspects of stroke with basic science contributions in areas of clinical interest. Reviews of current topics are broadly based to encompass not only recent advances of global interest but also those which may be more important in certain regions and the journal regularly features items of news interest from all parts of the world. To facilitate the international nature of the journal, our Associate Editors from Europe, Asia, North America and South America coordinate segments of the journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
